Alumis and Acelyrin sign ammended merger agreement

Alumis (ALMS) and Acelyrin (SLRN) announced an amendment to the existing terms of their previously announced merger agreement: Acelyrin stockholders will now receive 0.4814 shares of Alumis common stock for each share of Acelyrin common stock owned, representing an increase in the ownership percentage of the combined company over the original definitive merger agreement. With the amended exchange ratio, Alumis stockholders will own approximately 52% of the combined company and Acelyrin stockholders will own approximately 48% on a fully diluted basis. With a pro forma cash position of approximately $737M as of December 31, 2024, and continued operating discipline, Alumis expects runway to advance the combined company’s pipeline through multiple planned key data readouts across several clinical trials and to fund operating expenses and capital expenditure requirements into 2027. The amended merger agreement was unanimously recommended and approved by the disinterested directors of each company’s Board. Stockholders representing approximately 62% of Alumis voting common stock and approximately 24% of Acelyrin common stock have entered into voting agreements in support of the transaction. The companies continue to expect to close the transaction during Q2, subject to the approval by both companies’ stockholders and satisfaction of other customary closing conditions.